Import from '@/components/mdx'

Ezetimibe (Zetia) vs Lisinopril: Real-World Evidence Comparison for Women

What Each Drug Actually Does (and Why They Are Rarely Compared)

Ezetimibe and lisinopril are not competitors. They target completely different cardiovascular risk factors. Ezetimibe blocks the NPC1L1 transporter in the small intestine, cutting cholesterol absorption and reducing LDL by 18-25% as monotherapy. Lisinopril is an ACE inhibitor that prevents angiotensin I from converting to angiotensin II, relaxing blood vessels and reducing blood pressure by roughly 10-15 mmHg systolic at standard doses.

A woman is not switching from one to the other because they do the same job. She might be asking about both because her cardiometabolic risk panel has flagged two separate problems: elevated LDL and elevated blood pressure. Understanding each drug's evidence base, and how female physiology changes that evidence, is the practical goal of this article.

The Cardiometabolic Picture in Women Is Not the Same as in Men

Cardiovascular disease presents differently in women. Women develop coronary artery disease roughly a decade later than men, often after menopause, and their risk factors cluster differently. Hypertension prevalence surpasses men's after age 65, PCOS doubles or triples metabolic risk in the reproductive years, and the perimenopausal LDL surge is well documented but frequently undertreated.

Both drugs sit inside a larger prevention strategy. Neither replaces the other. The question is when each one belongs in your regimen and what the female-specific data say.

Ezetimibe (Zetia): What the Evidence Shows for Women

Ezetimibe's headline trial is IMPROVE-IT (NEJM 2015), which enrolled 18,144 patients after acute coronary syndrome. Adding ezetimibe 10 mg to simvastatin 40 mg reduced the composite of CV death, nonfatal MI, stroke, unstable angina, or revascularization from 34.7% to 32.7% over seven years, a relative risk reduction of 6.4% and an absolute risk reduction of 2%.

What IMPROVE-IT Said (and Did Not Say) About Women

Women made up only 24% of the IMPROVE-IT cohort. That is a meaningful evidence gap. The sex-stratified data showed a similar directional benefit from ezetimibe in women, but the trial was not powered to detect whether the effect size differed by sex. The evidence in women is extrapolated from a male-majority population, and WomanRx flags that openly.

What we do know from real-world registries and substudies is that women tend to tolerate ezetimibe well. Muscle-related side effects, the main reason women stop statins, are not a significant problem with ezetimibe because it does not work through the same hepatic CoA pathway.

How Hormonal Status Changes LDL and Ezetimibe's Role

During the reproductive years, estrogen raises HDL and modestly suppresses LDL. LDL often rises 10-15% in perimenopause as estrogen falls, sometimes crossing treatment thresholds for the first time. Women who have managed acceptable lipids for decades may suddenly need pharmacotherapy in their 40s or early 50s. Ezetimibe becomes relevant here as either a statin add-on or, for women who cannot tolerate statins, a monotherapy option.

In PCOS, insulin resistance drives elevated triglycerides and low HDL more than pure LDL elevation, but LDL particle quality (smaller, denser particles) also worsens. Ezetimibe is used off-label in PCOS dyslipidemia, though dedicated PCOS trials in this population are limited. Data are extrapolated from general dyslipidemia populations.

Postmenopausal Women and Ezetimibe

Post-menopause is when absolute cardiovascular risk in women rises sharply. The American College of Cardiology/AHA 2019 guideline positions ezetimibe as a reasonable non-statin add-on for very high-risk patients who cannot achieve adequate LDL lowering on maximum tolerated statin. For a postmenopausal woman with prior MI and statin intolerance, ezetimibe 10 mg daily is a real clinical option, not just a fallback.

Lisinopril: What the Evidence Shows for Women

Lisinopril belongs to the ACE inhibitor class. Its best-known large trial is ALLHAT (JAMA 2002), which enrolled 33,357 high-risk hypertensive patients aged 55 and older. ALLHAT compared lisinopril, amlodipine, and chlorthalidone (a thiazide diuretic). The primary outcome (fatal CHD or nonfatal MI) was similar across arms. But lisinopril performed worse than chlorthalidone on stroke prevention, with a 15% higher relative risk of stroke in the lisinopril arm.

Sex and Race Differences in ALLHAT

The ALLHAT sex-stratified results are instructive and sobering. Women and Black participants showed the least benefit from lisinopril relative to chlorthalidone, particularly for stroke. In Black participants, lisinopril had a 40% higher risk of stroke than chlorthalidone. Black women specifically were among those for whom thiazide diuretics outperformed lisinopril. This is partly explained by lower renin activity in Black patients, which makes ACE inhibitors less effective as blood-pressure-lowering agents.

The evidence matters for personalized prescribing. A Black woman with isolated hypertension and no proteinuria may achieve better stroke prevention with a thiazide or calcium channel blocker than with an ACE inhibitor.

Where Lisinopril Shines for Women

Lisinopril's strongest evidence in women is in specific comorbidity scenarios.

Diabetic kidney disease. Women with type 2 diabetes and microalbuminuria benefit from ACE inhibitors because they reduce intraglomerular pressure, slowing CKD progression independently of blood pressure. ACOG notes that ACE inhibitors are first-line for hypertension in women with diabetic nephropathy outside of pregnancy.

Heart failure with reduced ejection fraction (HFrEF). Lisinopril reduces hospitalizations and mortality in HFrEF. Women with peripartum cardiomyopathy who are no longer pregnant or breastfeeding may be started on lisinopril as part of guideline-directed medical therapy.

Post-MI remodeling. After myocardial infarction, ACE inhibitors reduce pathological left ventricular remodeling. Women are underrepresented in these trials too, but benefit is directionally consistent.

The Cough Problem Is More Common in Women

ACE inhibitor cough is the most common reason people stop lisinopril. Women are approximately twice as likely as men to develop ACE inhibitor-associated cough, with rates ranging from 10-20% in women versus 5-10% in men. This is not a minor nuisance. Persistent dry cough disrupts sleep, causes throat trauma, and leads to unnecessary workups for asthma or GERD. If you develop cough on lisinopril, tell your prescriber. Switching to an angiotensin receptor blocker (ARB) such as losartan or valsartan eliminates the cough while preserving the blood-pressure and kidney-protective benefits.

Perimenopausal and Postmenopausal Hypertension

Blood pressure often rises as women enter perimenopause, partly due to declining estrogen, increased sympathetic tone, and weight shifts toward central adiposity. Renin-angiotensin system activity changes with aging, which affects ACE inhibitor response. Some women do respond well to lisinopril in this stage, but real-world registry data suggest calcium channel blockers and thiazides remain first-line for most postmenopausal women without compelling indications for an ACE inhibitor.

Pregnancy, Lactation, and Contraception: A Required Section

This section is not optional reading. Both drugs carry significant pregnancy risks, and every woman of reproductive age needs to know this before starting either one.

Lisinopril in Pregnancy: Contraindicated Across All Trimesters

Lisinopril is FDA category D in the first trimester and category X in the second and third trimesters. ACE inhibitors cause fetal renal tubular dysplasia, oligohydramnios, neonatal anuria, pulmonary hypoplasia, limb contractures, and skull hypoplasia when used in the second or third trimester. First-trimester exposure carries risk of cardiovascular and CNS malformations, though data are less definitive.

If you are of childbearing age and starting lisinopril, you must use reliable contraception. If you become pregnant while taking lisinopril, stop it immediately and contact your prescriber and OB the same day. ACOG recommends switching to a pregnancy-safe antihypertensive such as labetalol, nifedipine extended-release, or methyldopa as soon as pregnancy is confirmed.

Ezetimibe in Pregnancy: Avoid, Data Are Thin

Ezetimibe has no adequate, well-controlled studies in pregnant women. Animal studies showed developmental toxicity at high doses. The FDA assigned no formal letter category under the current labeling system, but the manufacturer advises discontinuation during pregnancy. Cholesterol biosynthesis is necessary for fetal development, and disrupting intestinal absorption during organogenesis carries theoretical risk. If you discover a pregnancy while taking ezetimibe, discontinue it and consult your provider about whether statin therapy (also contraindicated) needs to be stopped as well.

Lactation Transfer

Ezetimibe and its active metabolite are excreted in rat breast milk; human data are absent. Given that breastfeeding is not urgent for a lipid-lowering indication, ezetimibe should be stopped during lactation. Lisinopril is present in breast milk at very low levels. Limited data suggest infant exposure is minimal, but most guidelines recommend avoiding it in breastfeeding given the availability of alternatives. The American Academy of Pediatrics previously listed enalapril (a related ACE inhibitor) as compatible with breastfeeding, but data for lisinopril specifically remain sparse. Discuss with your prescriber whether continuing is appropriate in your clinical situation.

Contraception Requirement

Any woman of reproductive age taking lisinopril should use effective contraception. An ACE inhibitor is a known teratogen; unplanned pregnancy while on this drug is a serious risk. This is not a hedge or a formality. Barrier methods alone are insufficient unless combined with another method. Long-acting reversible contraception (LARC) such as the copper IUD or hormonal IUD offers the most reliable protection.

Who Each Drug Is Right For, By Life Stage

This framework is designed to help you and your clinician match the right drug to the right problem at the right life stage. It does not replace a clinical assessment.

Reproductive Years (Ages 18-40)

Ezetimibe: Consider if you have familial hypercholesterolemia, statin intolerance, or PCOS with significant LDL elevation and are not pregnant or planning pregnancy soon. Requires reliable contraception.

Lisinopril: Consider if you have hypertension with diabetic nephropathy or stage-2 hypertension uncontrolled by lifestyle. Requires reliable contraception; stop immediately if you become pregnant.

Trying to Conceive or Pregnant

Ezetimibe: Discontinue at least one month before planned conception. No safe window in pregnancy.

Lisinopril: Stop before conception or immediately upon confirmed pregnancy. Switch to labetalol, nifedipine ER, or methyldopa as directed by your OB.

Perimenopause (Typical Range Ages 40-55)

Ezetimibe: A reasonable first addition to statin therapy when the perimenopausal LDL surge pushes you above your risk-based target. Tolerated well. Does not interact with menopausal hormone therapy at standard doses.

Lisinopril: Useful if rising blood pressure in perimenopause accompanies proteinuria or heart failure. Cough risk is real; plan a switch to an ARB if needed. Consider whether a thiazide or calcium channel blocker is a better fit first-line.

Post-Menopause

Ezetimibe: ACC/AHA guidelines support it as a non-statin add-on for very high-risk postmenopausal women. An absolute LDL reduction of roughly 14-18 mg/dL is clinically meaningful when LDL is already high after years of untreated perimenopausal rise.

Lisinopril: Strong evidence in HFrEF and diabetic nephropathy regardless of age. For isolated hypertension, ALLHAT data suggest thiazides may be a better first choice for many postmenopausal women.

Head-to-Head: How They Compare Across Key Clinical Dimensions

| Dimension | Ezetimibe (Zetia) | Lisinopril | |---|---|---| | Primary target | LDL cholesterol | Blood pressure | | LDL reduction | 18-25% | Minimal; not indicated | | SBP reduction | Minimal; not indicated | 10-15 mmHg | | Key trial | IMPROVE-IT (NEJM 2015) | ALLHAT (JAMA 2002) | | Women in key trial | 24% | ~49% | | Pregnancy | Avoid; discontinue | Contraindicated; teratogenic | | Lactation | Avoid; no human data | Avoid; sparse human data | | Female-specific side effect | None identified | Cough 2x more common in women | | PCOS relevance | Off-label for LDL component | If hypertension present | | Perimenopause relevance | LDL surge management | BP rise management | | Can be combined | Yes, routinely with statins | Yes, with diuretics, CCBs |

Real-World Evidence: What Happens Outside Clinical Trials

Randomized trial populations are not the same as real-world populations. Women, older adults, and those with multiple comorbidities are underrepresented in both IMPROVE-IT and ALLHAT.

Real-world data from insurance claims and electronic health record studies paint a more textured picture. A 2022 analysis from a large US claims database found that women are prescribed ACE inhibitors at lower rates than men with identical hypertension diagnoses, a finding that likely reflects clinician hesitancy around prescribing them to women of reproductive age. That hesitancy is medically appropriate for pregnancy risk but may lead to undertreatment in postmenopausal women who no longer face that concern.

Ezetimibe adherence data show that women discontinue the drug at similar rates to men, roughly 50% of patients have stopped within 12 months in real-world studies, often due to cost (ezetimibe remained brand-only until 2017) or low perceived urgency because the drug causes no noticeable symptoms when it works. Generic ezetimibe is now widely available at low cost, removing a major barrier.

Lisinopril adherence is hampered in women by cough. Real-world pharmacy switch data show that women are more likely than men to request a switch to an ARB within 6 months of starting an ACE inhibitor. ARBs (losartan, valsartan, olmesartan) provide equivalent or better blood-pressure control without the bradykinin-mediated cough. A 2021 Cochrane review confirmed that ARBs and ACE inhibitors have comparable cardiovascular outcomes but ARBs have significantly lower cough discontinuation rates.

Drug Interactions Relevant to Women

Ezetimibe Interactions

Ezetimibe is generally low-interaction. The main concern is with cyclosporine, which increases ezetimibe plasma levels significantly. For women taking cyclosporine after organ transplant, dose adjustment or avoidance may be needed. Colesevelam (a bile acid sequestrant) reduces ezetimibe absorption; space doses by at least 4 hours. Fibrates such as fenofibrate are sometimes combined with ezetimibe for mixed dyslipidemia in women with PCOS; the combination is generally safe but watch for gallstone risk with fibrates.

Lisinopril Interactions

NSAIDs blunt lisinopril's blood-pressure-lowering effect and increase the risk of acute kidney injury, a combination common in women who use ibuprofen for dysmenorrhea or joint pain. Potassium-sparing diuretics (spironolactone, eplerenone) combined with lisinopril raise hyperkalemia risk. Spironolactone is used in women for PCOS, acne, and hair loss; if your prescriber adds lisinopril, potassium monitoring is essential. Lithium levels rise with ACE inhibitor use, relevant for women on mood stabilizers.

Practical Monitoring for Women on These Drugs

On Ezetimibe

• Fasting lipid panel 4-12 weeks after starting or adjusting dose
• Liver enzymes only if combining with a statin (ezetimibe alone has minimal hepatotoxicity risk)
• No routine muscle enzyme monitoring unless symptomatic
• Annual lipid reassessment once at goal

On Lisinopril

• Basic metabolic panel (creatinine, potassium) at baseline and 1-2 weeks after starting or dose increase
• Blood pressure monitoring at home and at every visit
• Cough symptom check at 4-8 weeks; if present, plan ARB switch
• Urine microalbumin annually in women with diabetes or CKD
• Pregnancy test if any symptoms of pregnancy arise, and stop the drug immediately if positive

Should You Switch from Zetia to Lisinopril?

The short answer: almost certainly not, because they treat different problems. Switching makes no pharmacological sense unless your clinical picture has changed.

Scenarios where the question might arise:

Your doctor is adding lisinopril, not substituting it. If your LDL is controlled on ezetimibe and you have developed hypertension or heart failure, lisinopril is being added to your regimen, not replacing ezetimibe. Both drugs can be taken together without meaningful interaction.

Your cholesterol medications are being reconsidered and your prescriber also wants to address blood pressure. A full medication review is different from a swap. Ask your prescriber explicitly whether ezetimibe is being continued, paused, or stopped, and why.

You believe your prescriber is confused about what each drug does. This is rare but happens when care is fragmented. Ezetimibe lowers LDL; lisinopril lowers blood pressure. If a prescriber is telling you to stop a cholesterol medication to start a blood pressure medication without a clear reason, a second opinion from a cardiologist or internist is reasonable.

Dr. Elena Vasquez, WomanRx editorial board reviewer and internal medicine physician, notes: "I see women come in believing Zetia and lisinopril are interchangeable options for 'heart protection.' They are not. One cuts cholesterol absorption; the other relaxes blood vessels. A woman with both elevated LDL and stage-2 hypertension may need both drugs. The conversation should be about which risk factor to treat first and most aggressively, not which pill replaces which."